The KN510713 Study in Combination With mFOLFIRINOX

NCT07114861 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

DRUG: Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX
DRUG: Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX

Sponsor

New Cancer Cure-Bio Co.,Ltd.